Moderna, Inc. (Nasdaq: MRNA) has announced its participation in three upcoming investor conferences scheduled for late May and June 2025, providing opportunities for the company to update stakeholders on its mRNA medicine platform and pipeline developments.
Conference Schedule and Participation
The biotechnology company will present at Bernstein's 41st Annual Strategic Decisions Conference on Thursday, May 29th at 10:00am ET. Following this, Moderna is scheduled to participate in the Jefferies Global Health Care Conference on Thursday, June 5th at 10:30am ET, and the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 8:40am ET.
All presentations will be available via live webcast through the "Events and Presentations" section of Moderna's investor relations website at investors.modernatx.com. The company has confirmed that replay recordings of each webcast will be archived on its website for at least 30 days following each presentation.
mRNA Platform Leadership
Moderna describes itself as a leader in creating the field of mRNA medicine, working at the intersection of science, technology and health for more than a decade. The company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
The company's mRNA platform has enabled development across multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. Through advancement of mRNA technology, Moderna states it is reimagining how medicines are made and transforming approaches to treating and preventing disease.
Strategic Positioning
These investor presentations come as Moderna continues to leverage its established mRNA platform beyond COVID-19 applications. The company emphasizes its unique culture and global team driven by values and mindsets focused on responsibly changing the future of human health, with a stated goal of delivering the greatest possible impact to people through mRNA medicines.
The scheduled conferences represent key opportunities for Moderna to communicate its strategic direction and pipeline progress to the investment community during a period of continued expansion in mRNA therapeutic applications.
